De-escalation of Anti-platelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Narrative Review
Acute coronary syndromes (ACS) remain a leading cause of morbidity and mortality worldwide. The cornerstone of treatment for ACS, particularly in patients undergoing percutaneous coronary intervention (PCI), is dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor. The availability of different oral P2Y12 inhibitors, such as clopidogrel, prasugrel, and ticagrelor, has provided physicians with the flexibility to switch therapies based on specific clinical scenarios. However, the optimal timing, loading dose, and interval for transitioning between P2Y12 inhibitors remain controversial and require further evidence. This review aims to provide a comprehensive overview of the pharmacology of common P2Y12 inhibitors, definitions of de-escalation, different de-escalating strategies, and their outcomes, along with potential future directions in de-escalation therapy.
Introduction
ACS is primarily caused by thrombus formation in the coronary artery following the erosion or rupture of an atherosclerotic plaque. This triggers a cascade of intracellular signaling events driven by platelets and plasma components, leading to thrombus formation and subsequent vessel occlusion. Inhibition of both platelets and coagulation factors is essential for the treatment and secondary prevention of ACS. DAPT, which combines aspirin with a P2Y12 receptor antagonist, is the most preferred treatment to prevent atherothrombotic events in ACS patients and those undergoing PCI. Clopidogrel, prasugrel, and ticagrelor are the commonly used oral P2Y12 inhibitors. While clopidogrel has been widely prescribed, current guidelines favor prasugrel and ticagrelor due to their superior net clinical benefits in reducing thrombosis risk. However, safety concerns related to switching between these agents, such as increased bleeding risk, dyspnea, and cost, have led to the exploration of de-escalation strategies.
Properties of P2Y12 Receptor Inhibitors
P2Y12 inhibitors are classified into two principal classes: irreversibly and reversibly binding agents. Thienopyridines, including clopidogrel, prasugrel, and ticlopidine, are irreversibly binding inhibitors that require hepatic activation to bind covalently to the P2Y12 receptor. Clopidogrel, a second-generation thienopyridine, undergoes a two-step oxidation process by the cytochrome P450 (CYP) system to produce its active metabolite. Prasugrel, a third-generation thienopyridine, has a more potent pharmacokinetic profile than clopidogrel, requiring only a single step of hepatic oxidation. Reversibly binding inhibitors include cangrelor and ticagrelor. Ticagrelor, an oral agent, is directly active after administration and does not require hepatic activation. It has a rapid absorption rate with a half-life of 7 to 12 hours, necessitating twice-daily dosing. Ticagrelor reversibly binds to a distinct site on the P2Y12 receptor, preventing ADP from activating the P2Y12 pathway noncompetitively.
Interactions Between P2Y12 Inhibitors
ADP, released from dense granules of platelets, binds to P2Y1 and P2Y12 receptors on the platelet membrane, initiating platelet activation and thrombus formation. The P2Y12 receptor is a critical target in managing and preventing ACS. Safety concerns in switching between P2Y12 inhibitors arise from potential drug-drug interactions (DDIs), which can lead to inadequate platelet inhibition and increased thrombotic risk or excessive platelet inhibition and bleeding complications. The pharmacological properties of P2Y12 inhibitors, including half-life, site of action, mechanism of receptor binding, and the rate of onset and offset of pharmacodynamic effects, play a significant role in these interactions.
Common DAPT
The benefits of DAPT following ACS are well-established by various trials, including CURE, COMMIT/CCS-2, and CLARITY-TIMI 28. Clopidogrel, when combined with aspirin, reduces the 1-year incidence of cardiovascular events compared to aspirin alone. This observation was further supported by the PLATO and TRITON trials, which demonstrated the efficacy of ticagrelor and prasugrel in combination with aspirin. The DAPT trial showed that continued thienopyridine and aspirin therapy beyond 1 year after drug-eluting stent (DES) placement significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events, albeit with an increased risk of bleeding. The PEGASUS-TIMI 54 trial evaluated the combination of aspirin and ticagrelor in patients with a previous myocardial infarction (MI), showing a reduction in cardiovascular death, MI, or stroke but an increased rate of major bleeding.
De-escalation Background and Definitions
De-escalation of antiplatelet therapy in ACS patients aims to reduce the intensity of treatment, such as switching P2Y12 receptor inhibitors, reducing their dose, shortening the duration of DAPT, or transitioning to early-stage P2Y12 receptor inhibitor monotherapy. The need for de-escalation arises from major bleeding events, adverse reactions (e.g., dyspnea), the need for concomitant oral anticoagulation, and cost considerations. De-escalation modalities include early-stage potent P2Y12 receptor inhibitor monotherapy, reducing the dose of P2Y12 inhibitors, shortening the duration of DAPT, and switching from novel P2Y12 inhibitors (ticagrelor or prasugrel) to clopidogrel.
De-escalating Studies and Outcomes
Early-Stage Potent P2Y12 Receptor Inhibitor Monotherapy
Current guidelines recommend DAPT with aspirin and a potent P2Y12 inhibitor, particularly ticagrelor, for patients with coronary stents. The TWILIGHT trial is investigating the hypothesis that ticagrelor monotherapy is superior to DAPT in reducing bleeding in high-risk ACS patients who received DAPT 3 months after PCI. The GLOBAL LEADERS trial compared ticagrelor combined with acetylsalicylic acid (ASA) and ticagrelor monotherapy to conventional DAPT in patients undergoing DES implantation. The trial found no significant difference in all-cause death or non-fatal MI between the experimental and control groups, and the incidence of bleeding events did not differ significantly.
Reducing the Dose of P2Y12 Receptor Inhibitors
Ticagrelor is recommended over clopidogrel in both European and American ACS guidelines. The PLATO study demonstrated that ticagrelor reduces atherothrombotic events in ACS patients. The PEGASUS-TIMI 54 trial showed that ticagrelor 60 mg twice daily was as effective as the 90 mg dose in reducing cardiovascular events but had a lower rate of adverse events, making it a more attractive long-term option. The ELECTRA pilot study is evaluating the effect of reducing the maintenance dose of ticagrelor on platelet inhibition in stable patients after MI treated with PCI.
Shortening the Duration of DAPT
Current guidelines recommend continuing DAPT for 1 year in ACS patients. However, concerns about long-term use of DAPT, including increased bleeding events and all-cause mortality, have led to the exploration of shorter durations. Recent trials, such as RESET, OPTIMIZE, ITALIC, ISAR-SAFE, and EXCELLENT, have shown that shorter durations of DAPT (3–6 months) are non-inferior to 12 months in terms of cardiovascular events and major bleeding. The SMART-DATE trial found that a 6-month duration of DAPT was non-inferior to 12 months in ACS patients, although MI occurred more frequently in the 6-month group. The OPT-PEACE trial is evaluating the optimal DAPT duration to reduce gastrointestinal mucosal injury.
Switching Potent P2Y12 Inhibitors to Clopidogrel
International guidelines recommend potent platelet inhibition with prasugrel or ticagrelor in the first year after ACS. However, early de-escalation to clopidogrel is appealing for medical and economic reasons. The TOPIC study showed that de-escalation to aspirin plus clopidogrel after 1 month of event-free treatment with a new-generation P2Y12 inhibitor reduced bleeding complications. The TROPICAL-ACS trial demonstrated that guided de-escalation to clopidogrel was non-inferior to standard treatment with prasugrel in terms of net clinical benefit. Pharmacodynamic studies have shown that switching from prasugrel or ticagrelor to clopidogrel increases platelet reactivity and high platelet reactivity (HPR) rates but may reduce bleeding events.
Switching from Ticagrelor to Clopidogrel
Data on the optimal switching from ticagrelor to clopidogrel are limited. Pharmacodynamic data suggest that a 600 mg loading dose of clopidogrel should be given when switching from ticagrelor therapy. The SWAP-4 study evaluated the optimal strategy for de-escalation from ticagrelor to clopidogrel based on pharmacodynamic effects, showing that de-escalation is associated with an increase in platelet reactivity, which can be mitigated by using a loading dose before initiating a maintenance dose regimen.
Practical Problems to be Solved
Period of De-escalation
The optimal timing for de-escalation remains uncertain, with variations in regional DAPT practices and switching protocols. Current guidelines are based on evidence that predates technological advances, such as second-generation DES, and many studies are underpowered to detect differences due to low event rates. Future studies are needed to define the best strategy for de-escalation and provide meaningful recommendations.
Personalized Medicine
Personalized medicine aims to identify individuals who are more or less likely to benefit from de-escalation or switching protocols. Tailored antiplatelet strategies, such as platelet function testing (PFT) or CYP2C19 genotyping, show promise but require further research to define prediction tools with high discriminatory value in real-world settings.
Conclusion
Switching between P2Y12 inhibitors is common in clinical practice, but the clinical effects of most switching strategies are not fully determined. Current evidence suggests that de-escalation in low ischemic risk patients offers comparable antiplatelet efficacy with reduced bleeding events. However, further clinical studies are needed to substantiate the long-term benefits of de-escalation protocols. Physicians must weigh the benefits and risks of higher or lower platelet inhibition in their patients, balancing the reduction of ischemic events with bleeding risks as the patient’s condition evolves.
doi.org/10.1097/CM9.0000000000000047
Was this helpful?
0 / 0